Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Income from Continuing Operations (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Income from Continuing Operations data on record, last reported at 203577000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 460.37% year-over-year to 203577000.0; the TTM value through Dec 2025 reached 122238000.0, up 38.23%, while the annual FY2025 figure was 122238000.0, 38.23% up from the prior year.
  • Income from Continuing Operations reached 203577000.0 in Q4 2025 per APLS's latest filing, down from 215715000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 402697000.0 in Q4 2022 and bottomed at 219191000.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 59938500.0, with a median of 107131000.0 recorded in 2023.
  • The widest YoY moves for Income from Continuing Operations: up 475.52% in 2025, down 460.37% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 283396000.0 in 2021, then surged by 42.1% to 402697000.0 in 2022, then crashed by 109.95% to 40081000.0 in 2023, then grew by 9.36% to 36329000.0 in 2024, then crashed by 460.37% to 203577000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 203577000.0 in Q4 2025, 215715000.0 in Q3 2025, and 42151000.0 in Q2 2025.